Bicara Therapeutics (BCAX) Competitors $17.59 +0.99 (+5.96%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends BCAX vs. OGN, PTCT, VRNA, RYTM, MLTX, EWTX, JANX, XENE, MRUS, and ACADShould you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include Organon & Co. (OGN), PTC Therapeutics (PTCT), Verona Pharma (VRNA), Rhythm Pharmaceuticals (RYTM), MoonLake Immunotherapeutics (MLTX), Edgewise Therapeutics (EWTX), Janux Therapeutics (JANX), Xenon Pharmaceuticals (XENE), Merus (MRUS), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry. Bicara Therapeutics vs. Organon & Co. PTC Therapeutics Verona Pharma Rhythm Pharmaceuticals MoonLake Immunotherapeutics Edgewise Therapeutics Janux Therapeutics Xenon Pharmaceuticals Merus ACADIA Pharmaceuticals Bicara Therapeutics (NASDAQ:BCAX) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings, dividends and community ranking. Which has stronger earnings & valuation, BCAX or OGN? Organon & Co. has higher revenue and earnings than Bicara Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicara TherapeuticsN/AN/AN/AN/AN/AOrganon & Co.$6.41B0.59$1.02B$5.042.89 Do analysts prefer BCAX or OGN? Bicara Therapeutics currently has a consensus target price of $43.00, suggesting a potential upside of 144.46%. Organon & Co. has a consensus target price of $21.33, suggesting a potential upside of 46.32%. Given Bicara Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Bicara Therapeutics is more favorable than Organon & Co..Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Organon & Co. 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Do institutionals and insiders believe in BCAX or OGN? 77.4% of Organon & Co. shares are held by institutional investors. 1.4% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in BCAX or OGN? Organon & Co. received 10 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Bicara Therapeutics an outperform vote while only 34.00% of users gave Organon & Co. an outperform vote. CompanyUnderperformOutperformBicara TherapeuticsOutperform Votes7100.00% Underperform VotesNo VotesOrganon & Co.Outperform Votes1734.00% Underperform Votes3366.00% Is BCAX or OGN more profitable? Organon & Co. has a net margin of 20.30% compared to Bicara Therapeutics' net margin of 0.00%. Organon & Co.'s return on equity of 644.70% beat Bicara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bicara TherapeuticsN/A N/A N/A Organon & Co. 20.30%644.70%8.12% Does the media prefer BCAX or OGN? In the previous week, Organon & Co. had 2 more articles in the media than Bicara Therapeutics. MarketBeat recorded 5 mentions for Organon & Co. and 3 mentions for Bicara Therapeutics. Organon & Co.'s average media sentiment score of 0.65 beat Bicara Therapeutics' score of 0.62 indicating that Organon & Co. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Organon & Co. 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryOrganon & Co. beats Bicara Therapeutics on 9 of the 13 factors compared between the two stocks. Ad ProsperityPubThis Indicator called BOTH NVDA ralliesRarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… Click this link here. Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAX vs. The Competition Export to ExcelMetricBicara TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$957.18M$6.57B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E RatioN/A10.4289.5817.17Price / SalesN/A195.801,116.12116.95Price / CashN/A57.1642.8237.86Price / BookN/A5.094.774.78Net IncomeN/A$151.83M$120.15M$225.60M7 Day Performance0.51%-2.13%-1.92%-1.23%1 Month Performance0.03%-3.10%11.47%3.36%1 Year PerformanceN/A11.54%30.54%16.60% Bicara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCAXBicara TherapeuticsN/A$17.59+6.0%$43.00+144.5%N/A$957.18MN/A0.0032News CoverageGap DownHigh Trading VolumeOGNOrganon & Co.4.8014 of 5 stars$14.72-3.8%$21.33+44.9%+10.9%$3.79B$6.26B2.9110,000PTCTPTC Therapeutics3.6566 of 5 stars$47.77+3.0%$54.08+13.2%+71.0%$3.68B$937.82M-7.811,410Analyst DowngradeVRNAVerona Pharma0.7049 of 5 stars$43.32+4.6%$43.83+1.2%+153.4%$3.52B$460,000.00-21.5730Positive NewsRYTMRhythm Pharmaceuticals4.1121 of 5 stars$56.23+1.8%$63.70+13.3%+25.1%$3.46B$77.43M-12.76140Analyst ForecastNews CoveragePositive NewsMLTXMoonLake Immunotherapeutics1.6268 of 5 stars$52.07+1.4%$79.88+53.4%-9.3%$3.33BN/A-39.802EWTXEdgewise Therapeutics2.7263 of 5 stars$34.97+26.6%$42.33+21.1%+261.7%$3.31BN/A-22.8560Analyst ForecastAnalyst RevisionGap UpHigh Trading VolumeJANXJanux Therapeutics3.6708 of 5 stars$62.25+1.9%$89.90+44.4%+496.3%$3.27B$13.05M-52.2330Positive NewsXENEXenon Pharmaceuticals2.7945 of 5 stars$41.15+2.7%$56.90+38.3%-5.8%$3.14B$9.43M-14.20251Insider TradeMRUSMerus2.8078 of 5 stars$42.84+0.0%$85.64+99.9%+61.7%$2.93B$43.95M-10.8437ACADACADIA Pharmaceuticals3.8468 of 5 stars$17.50+1.4%$25.60+46.3%-41.9%$2.91B$726.44M22.13510 Related Companies and Tools Related Companies OGN Competitors PTCT Competitors VRNA Competitors RYTM Competitors MLTX Competitors EWTX Competitors JANX Competitors XENE Competitors MRUS Competitors ACAD Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BCAX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
